Marx Wolfgang, Skvarc David R, Mohebbi Mohammadreza, Walker Adam J, Meehan Alcy, Turner Alyna, Baker Andrea, Dodd Seetal, Cotton Sue M, Scott James Graham, Kavanagh Bianca E, Ashton Melanie M, Brown Ellie, McGrath John J, Berk Michael, Dean Olivia May
Deakin University, The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Geelong, VIC, Australia.
Biostatistics Unit, Faculty of Health, Deakin University, Geelong, VIC, Australia.
Front Psychiatry. 2021 Jun 15;12:626486. doi: 10.3389/fpsyt.2021.626486. eCollection 2021.
Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen ( Linn.) pericarp extract may be an effective intervention to improve cognitive performance in this population. This was a secondary analysis of a larger randomized placebo-controlled trial that investigated a 24-weeks intervention of mangosteen pericarp extract supplementation in people diagnosed with schizophrenia. A subset of = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted. ANZCTR.org.au identifier: ACTRN12616000859482, registered 30 June 3 2016.
认知障碍在精神分裂症患者中很常见，且往往负担沉重。本研究的目的是调查山竹果皮提取物是否可能是改善该人群认知表现的有效干预措施。这是一项对一项更大规模的随机安慰剂对照试验的二次分析，该试验研究了对被诊断为精神分裂症的患者进行为期24周的山竹果皮提取物补充干预。本分析纳入了随访时完成认知结果的n = 114名参与者的一个子集。使用Cogstate简版测试组合，评估了以下认知结果：精神运动功能、注意力、视觉学习和记忆（视觉和工作记忆）。亚组分析调查了基线临床参数（基线认知功能、疾病严重程度和病程、抑郁症状）是否调节了山竹果皮提取物干预与认知结果变化之间的关系。在所评估的任何认知结果中，组间均无显著变化。基于基线认知和临床特征的亚组分析未发现组间变化存在任何显著差异。山竹果皮提取物对精神分裂症患者的认知结果没有影响。可能需要进一步研究山竹干预的最佳给药策略以及对其他认知领域进行测试。澳大利亚新西兰临床试验注册中心标识符：ACTRN12616000859482，于2016年6月30日注册。
